Cargando…

The Pathological Features of Colorectal Cancer Determine the Detection Performance on Blood ctDNA

BACKGROUND AND AIM: Methylated SEPT9 is a novel circulating tumor DNA marker for colorectal cancer, while the effects of various colorectal cancer clinicopathological factors on its detection performance have not been fully evaluated. This study aims to investigate the significance of the clinicopat...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Na, Song, Lele, Kang, Qian, Jin, Peng, Cai, Guoxiang, Zhou, Jinfeng, Zhou, Guangpeng, Sheng, Jianqiu, Cai, Sanjun, Wang, Jianming, Han, Xiaoliang, Nie, Yongzhan, Wu, Kaichun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6144579/ https://www.ncbi.nlm.nih.gov/pubmed/30223720 http://dx.doi.org/10.1177/1533033818791794

Ejemplares similares

Algorithm Optimization in Methylation Detection with Multiple RT-qPCR
por: Song, Lele, et al.
Publicado: (2016)

Pathological Features and Survival Outcomes of Young Patients with Operable Colon Cancer: Are They Homogeneous?
por: Li, Qingguo, et al.
Publicado: (2014)

The association of blood ctDNA levels to mutations of marker genes in colorectal cancer
por: Bai, Fei, et al.
Publicado: (2023)

Prognostic Value of ctDNA Mutation in Melanoma: A Meta-Analysis
por: Zheng, Yang, et al.
Publicado: (2021)

ctDNA to Guide Adjuvant Therapy in Localized Colorectal Cancer (CRC)
por: Masfarré, Laura, et al.
Publicado: (2021)

Role of ctDNA in Breast Cancer
por: Sant, Marta, et al.
Publicado: (2022)

The Role of ctDNA in Gastric Cancer
por: Mencel, Justin, et al.
Publicado: (2022)

Utility of ctDNA Liquid Biopsies from Cancer Patients: An Institutional Study of 285 ctDNA Samples
por: Gumà, Josep, et al.
Publicado: (2022)

Ultrasensitive tumour‐agnostic non‐invasive detection of colorectal cancer recurrence using ctDNA methylation
por: Xiao, Yu, et al.
Publicado: (2022)

Association of ctDNA detection and recurrence assessment in patients with neoadjuvant treatment
por: Zhou, Jiaxin, et al.
Publicado: (2023)

Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer
por: Zhang, Sheng, et al.
Publicado: (2019)

Human oral microbiome dysbiosis as a novel non-invasive biomarker in detection of colorectal cancer
por: Zhang, Sheng, et al.
Publicado: (2020)

A dual biomarker detection platform for quantitating circulating tumor DNA (ctDNA)
por: Cai, Chunyan, et al.
Publicado: (2018)

Effect of Lymph Node Count on Pathological Stage III Rectal Cancer with Preoperative Radiotherapy
por: Li, Qingguo, et al.
Publicado: (2015)

Downregulation of S100A4 expression by RNA interference suppresses cell growth and invasion in human colorectal cancer cells
por: HUANG, LIYONG, et al.
Publicado: (2011)

Clinicopathological and genetic features of Chinese hereditary nonpolyposis colorectal cancer (HNPCC)
por: Liu, Fangqi, et al.
Publicado: (2014)

Multiplex detection of ctDNA mutations in plasma of colorectal cancer patients by PCR/SERS assay
por: Lyu, Nana, et al.
Publicado: (2020)

ctDNA and Adjuvant Therapy for Colorectal Cancer: Time to Re-Invent Our Treatment Paradigm
por: Naidoo, Mahendra, et al.
Publicado: (2021)

Prognostic and predictive value of Immunoscore and its correlation with ctDNA in stage II colorectal cancer
por: Wang, Fulong, et al.
Publicado: (2023)

Liquid Biopsy, ctDNA Diagnosis through NGS
por: Lin, Chen, et al.
Publicado: (2021)

ctDNA as a biomarker of progression in oesophageal adenocarcinoma
por: Bonazzi, V.F., et al.
Publicado: (2022)

State of the Art: ctDNA in Upper Gastrointestinal Malignancies
por: Labiano, Ibone, et al.
Publicado: (2023)

Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study
por: Wang, Yaqi, et al.
Publicado: (2021)

ctDNA as a prognostic biomarker in resectable CLM: Systematic review and meta-analysis
por: Wang, Da, et al.
Publicado: (2023)

Increased number of negative lymph nodes is associated with improved cancer specific survival in pathological IIIB and IIIC rectal cancer treated with preoperative radiotherapy
por: Li, Qingguo, et al.
Publicado: (2014)

ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors
por: Nie, Wei, et al.
Publicado: (2022)

The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: Novel prognostic indexes based on ctDNA
por: Liu, Binliang, et al.
Publicado: (2022)

Potential value of ctDNA monitoring in metastatic HR + /HER2 − breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial
por: Chiu, Joanne, et al.
Publicado: (2023)

Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients
por: Vidal, J, et al.
Publicado: (2017)

ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper
por: Dasari, Arvind, et al.
Publicado: (2020)

Response prediction by mutation- or methylation-specific detection of ctDNA dynamics in pretreated metastatic colorectal cancer
por: Doleschal, Bernhard, et al.
Publicado: (2023)

The diagnostic value of circulating tumor cells and ctDNA for gene mutations in lung cancer
por: Lyu, Mengyuan, et al.
Publicado: (2019)

The preoperative SUVmax for (18)F-FDG uptake predicts survival in patients with colorectal cancer
por: Shi, Debing, et al.
Publicado: (2015)

The Role of Dynamic ctDNA Monitoring During Combination Therapies of BRAF V600E-Mutated Metastatic Colorectal Cancer: A Case Report
por: Wang, Zhan, et al.
Publicado: (2020)

Better Long-Term Survival in Young Patients with Non-Metastatic Colorectal Cancer after Surgery, an Analysis of 69,835 Patients in SEER Database
por: Li, Qingguo, et al.
Publicado: (2014)

Feasibility of Longitudinal ctDNA Assessment in Patients with Uterine and Extra-Uterine Leiomyosarcoma
por: Zhou, Maggie, et al.
Publicado: (2022)

Detection of ctDNA in the plasma of patients with papillary thyroid carcinoma
por: Li, Huiqiang, et al.
Publicado: (2019)

ctDNA: An emerging neoadjuvant biomarker in resectable solid tumors
por: Abbosh, Christopher, et al.
Publicado: (2021)

Current status of ctDNA in precision oncology for hepatocellular carcinoma
por: Li, Yan, et al.
Publicado: (2021)

The potential, analysis and prospect of ctDNA sequencing in hepatocellular carcinoma
por: Ding, Yubo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ffvsqd9589kp95poiffrv2h19f